Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 4, 2021

Guardant Health seeks approval for liquid biopsy test in Japan

Guardant Health Asia, Middle East & Africa (AMEA) affiliate Guardant Health Japan has submitted an application to the Ministry of Health, Labour and Welfare (MHLW), seeking regulatory approval for a liquid biopsy test for tumour mutation profiling.

Guardant Health Asia, Middle East & Africa (AMEA) affiliate Guardant Health Japan has submitted an application to the Ministry of Health, Labour and Welfare (MHLW), seeking regulatory approval for a liquid biopsy test for tumour mutation profiling.

Guardant360 CDx is comprehensive genomic profiling (CGP) test, which uses blood samples from patients with advanced cancerous tumours.

Guardant Health AMEA CEO and Guardant Health Japan representative director Simranjit Singh said: “I am delighted to announce that we have submitted the regulatory application for Guardant360 CDx liquid biopsy test for approval by MHLW.

“Several clinical studies have shown that compared to invasive tissue-based testing, Guardant360 has a quicker turnaround time for reporting comprehensive genomic test results.

“For the patient, this means a shorter waiting time to get the most appropriate treatment while avoiding safety risks related to tissue biopsies.”

The test evaluates circulating tumour DNA (ctDNA) from the blood samples of advanced solid tumour patients and detects genetic alterations that could aid in treatment decisions.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

Guardant Health has also filed an application for Companion Diagnostic (CDx) approval of Guardant360 CDx.

Last August, the US Food and Drug Administration (FDA) approved the Guardant360 CDx for comprehensive genomic profiling across all solid cancers.

It was also approved as a companion diagnostic for detecting non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) alterations who may benefit from Tagrisso (osimertinib) treatment.

Guardant Health Japan noted that it is the first FDA-approved liquid biopsy test for complete tumour mutation profiling across all solid cancers.

The company intends to contribute to precision oncology in the country by supporting research and development efforts and drive broad clinical adoption of its products.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU